Real-world experience of Impower150 regimen for EGFR+ NSCLC

• Date :
• 0    
  0

Molecular testing for lung cancer in England

• Date :
• 0    
  0

Lung cancer frailty research

• Date :
• 0    
  0

Brain metastases in ALK+ NSCLC

• Date :
• 0    
  0

NICE rejection of osimertinib: what does this mean for EGFR+ NSCLC in the UK?

• Date :
• 0    
  0

New screening and therapy strategies for SCLC

• Date :
• 0    
  0

Frontline ALK+ NSCLC management

• Date :
• 0    
  0

Analyzing the National Lung Cancer Audit (NLCA)

• Date :
• 0    
  0

Lung cancer: actionable targets

• Date :
• 0    
  0

Lung cancer palliation in Scotland

• Date :
• 0    
  0

Circulating DNA testing commercially available

• Date :
• 0    
  0

Concurrent immunotherapy in SCLC

• Date :
• 0    
  0

How to achieve an early and fast lung cancer diagnosis?

• Date :
• 0    
  0

Patient feedback: lung cancer nurse specialists

• Date :
• 0    
  0

Lung cancer molecular testing in the UK

• Date :
• 0    
  0

Checkpoint inhibitor resistance in lung cancer

• Date :
• 0    
  0

Lung cancer: the issues around late diagnosis

• Date :
• 0    
  0

Access to lung cancer care in the UK: UKLCC report

• Date :
• 0    
  0

SPORT study: second primary lung cancer

• Date :
• 0    
  0

Lung cancer: helping CNS’s help patients

• Date :
• 0    
  0

UKLCC: early diagnosis

• Date :
• 0    
  0

Diagnosis to end of life care: an evolving journey

• Date :
• 0    
  0

The role of BTOG annual meeting

• Date :
• 0    
  0

NCRI Lung Cancer Study Group: clinical trials

• Date :
• 0    
  0

Lung cancer: how can we stop missing it?

• Date :
• 0    
  0

NSCLC: care gaps in England

• Date :
• 0    
  0

ECLS: preventing late-stage lung cancer

• Date :
• 0    
  0

NLCA: addressing deficiencies in care

• Date :
• 0    
  0

Looking to the future of screening programs for lung cancer in the UK

• Date :
• 0    
  0

UK excels at molecular testing for lung cancer

• Date :
• 0    
  0

Systemic treatment following immunotherapy

• Date :
• 0    
  0

UK needs to improve interface of primary/secondary care for cancer

• Date :
• 0    
  0

The impact of brain metastasis

• Date :
• 0    
  0

Where are we with lung cancer?

• Date :
• 0    
  0

ADSCaN trial: testing accelerated radiotherapy in NSCLC

• Date :
• 0    
  0

NHS resourcing issues and routes to fixing them

• Date :
• 0    
  0

Where is the management of lung cancer moving?

• Date :
• 0    
  0

NSCLC: filling the gaps

• Date :
• 0    
  0

Resourcing and differing opinions for treating NSCLC with brain mets

• Date :
• 0    
  0

Neuroendocrine morphology

• Date :
• 0    
  0

Managing ALK+ NSCLC

• Date :
• 0    
  0

AI to improve cancer imaging

• Date :
• 0    
  0

Radiotherapy: do WBRT/PCI still have a role in NSCLC/SCLC?

• Date :
• 0    
  0

EORTC Lung Cancer Group update

• Date :
• 0    
  0

The tumor microenvironment: lung cancer

• Date :
• 0    
  0

NGS & single-gene testing: lung cancer

• Date :
• 0    
  0

Equity of access: NHS molecular diagnostics

• Date :
• 0    
  0

Liquid vs tissue biopsy in lung cancer

• Date :
• 0    
  0

New agents for EGFR+ NSCLC: osimertinib and beyond

• Date :
• 0    
  0

Actionable lung cancer targets

• Date :
• 0    
  0

Quitting: is vaping effective for patients?

• Date :
• 0    
  0

ALTA-1L: brigatinib vs crizotinib in NSCLC

• Date :
• 0    
  0

Prof. Popat: BTOG 2020 hot topics

• Date :
• 0    
  0

ALTA-1L: brigatinib vs crizotinib in ALK+ aNSCLC

• Date :
• 0    
  0

Chemoimmunotherapy, the UK & extensive-stage SCLC

• Date :
• 0    
  0

NICE osimertinib rejection: UK patients

• Date :
• 0    
  0

ALTA-1L: brigatinib vs crizotinib

• Date :
• 0    
  0

Importance of occupational therapy for patients in early clinical trials

• Date :
• 0    
  0

Lung cancer nursing: best practice

• Date :
• 0    
  0

Liquid biopsy testing in lung cancer

• Date :
• 0    
  0

Introducing liquid biopsies in lung cancer: critical thinking

• Date :
• 0    
  0

Incidence of pneumonitis in patients undergoing immunotherapy

• Date :
• 0    
  0

Mesothelioma trials update: CONFIRM, BEAT-meso & MARS2

• Date :
• 0    
  0

Denis Talbot: lifetime achievement award winner

• Date :
• 0    
  0

Early diagnosis: clinical implications

• Date :
• 0    
  0

The vaping-related lung injury epidemic

• Date :
• 0    
  0

Dr Rintoul: BTOG 2020 highlights

• Date :
• 0    
  0

Painting the lung cancer cell picture

• Date :
• 0    
  0

A shifting paradigm: lung cancer

• Date :
• 0    
  0

The importance of molecular testing

• Date :
• 0    
  0

Chemo-IO, IO-IO, or IO-mono: which is correct for lung cancer?

• Date :
• 0    
  0

Whole body MRI the future for lung cancer staging

• Date :
• 0    
  0

Late diagnosis of lung cancer in the UK

• Date :
• 0    
  0

Management of frontline ALK+ NSCLC: brigatinib vs. Alectinib

• Date :
• 0    
  0

Antidrug antibodies against CPIs

• Date :
• 0    
  0

Lung cancer screening in the UK

• Date :
• 0    
  0

Lung Cancer: post-frontline immunotherapy

• Date :
• 0    
  0

Dr Newsom-Davis: BTOG 2020 highlights & priorities

• Date :
• 0    
  0

Early Diagnosis Matters: UK Lung Cancer Coalition

• Date :
• 0    
  0

Stephen Liu: BTOG highlights

• Date :
• 0    
  0

Liquid biopsy: a new era

• Date :
• 0    
  0

QoL, exercise & lung cancer

• Date :
• 0    
  0

Mesothelioma: MARS2 & MesoTRAP

• Date :
• 0    
  0

Les 13es Journées Pratiques Respiration Sommeil - JPRS 2025

• Date :
• 3569    
  0

29e Congrès de Pneumologie de Langue Française - CPLF 2025

• Date :
• 4598    
  0

CHEST Congress 2024

• Date :
• 8516    
  0

The European Respiratory Congress - ERS 2024

• Date :
• 3291    
  0

The Annual Congress of The South African Thoracic Society-SATS 2024

• Date :
• 3709    
  0